argenx Subcutaneous Vyvgart Enters the Mix
The FDA approved argenx' subcutaneous version of Vyvgart (‘Vyvgart Hytrulo'), based on the Phase III bridging study that showed non-inferiority vs IV Vyvgart. Vyvgart Hytrulo will be available for AChR+ gMG patients at net pricing parity to the IV variant. We believe the new modality provides for a more patient-friendly solution despite its HCP administration only. We increase our TP from € 400 to € 420 and maintain a BUY rating.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.